Skip to main content

Table 1 Cell cycle distribution (%)

From: Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines

HT-29

G 0/G 1

S

G 2/M

NT

59,24

27,52

13,24

E

53,82

36,92

9,26

Cx5

56,97

28,55

14,48

Cx10

65,01

27,06

7,93

Gb

55,08

32,88

12,04

Cx5+E

53,24*

30,08

16,68

Cx10+E

48,41

36,03

15,56

Gb+E

54,41

37,89

7,7

Caco-2

G 0 / G 1

S

G 2 / M

NT

66,25

20

13,75

E

55,1*

26,69

18,21

Cx5

73,73

15,36

10,91

Cx10

72,50

15,38

12,12

Gb

70,04

18,5

11,46

Cx5+E

57,20

21,13

21,67

Cx10+E

56,01*

24,02

19,97

Gb+E

66,35

26,52

7,13

  1. NT = untreated; E = Epidermal growth factor 10 nmol/L; Cx5 = cetuximab 5 nmol/L; Cx10 = cetuximab 10 nmol/L; Gb = gefitinib 1 μmol/L; Cx5 + E = cetuximab 5 nmol/L + Epidermal growth factor 10 nmol/L; Cx10 + E = cetuximab 10 nmol/L + Epidermal growth factor 10 nmol/L; Gb + E = gefitinib 1 μmol/L + Epidermal growth factor 10 nmol/L. ANOVA One-way analysis of variance Tukey's Multiple Comparison Test. Each point represents a mean of quadruplicate values.
  2. *Statistically Significant
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us